PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)- DIBENZENAHEPTAPHANE-74-CARBOXAMIDE

An amorphous solid dispersion stabilized by PVP and using specific solvents addresses bioavailability and stability issues in solid dosage forms of active ingredient I, enabling effective treatment of thrombotic disorders with small, stable tablets.

UA131338C2Active Publication Date: 2026-10-21BAYER AG
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
UA202304712
Authority / Receiving Office
UA · UA
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-03-09
Filing Date
2022-03-04
Publication Date
2026-10-21
Estimated Expiration
2042-03-04

AI Technical Summary

Technical Problem

Existing solid dosage forms of the active substance (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient I) suffer from reduced bioavailability, instability, and enantiomeric impurity issues, leading to ineffective treatment of thrombotic or thromboembolic disorders.

Method used

Development of an amorphous solid dispersion (ASD) containing active ingredient I in a pharmaceutically acceptable matrix, stabilized by polyvinylpyrrolidone (PVP) and using a wet granulation method, ensuring high drug load and maintaining enantiomeric purity, with solvents like ethanol and acetone enhancing solubility.

Benefits of technology

The amorphous solid dispersion achieves excellent dissolution behavior, good bioavailability, and stability of active ingredient I, allowing for small tablet sizes and effective treatment of cardiovascular and ophthalmological disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000030_0000
    Figure 00000030_0000
Patent Text Reader

Abstract

The present invention relates to amorphous solid dispersions (ASD) and solid pharmaceutical dosage forms for oral administration comprising (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-5 dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptaphane-74-carboxamide (active ingredient (I)), characterized in that the active ingredient (I) is immediately released from the amorphous solid dispersions (ASD) and the solid pharmaceutical dosage forms for oral administration, and also methods for the preparation thereof, use thereof as medicaments, and also use thereof for the treatment and / or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
Need to check novelty before this filing date? Find Prior Art

Description

This invention relates to amorphous solid dispersions (ASD) and solid pharmaceutical dosage forms. for oral administration, including (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14- (trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzene-heptaphane-74-carboxamide (active substance (I)), characterized in that the active substance (I) is immediately released from amorphous solids dispersions (ASD) and solid dosage forms for oral administration, as well as methods for their preparation, use as medicinal products, as well as use for the treatment and / or prevention of diseases, in particular cardiovascular disorders, mainly thrombotic or thromboembolic disorders, and edema, and also ophthalmological disorders. Active substance (I), (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)- Pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide, also known as 4-({(2S)-2-[4-{5- chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2- fluorobenzamide, known from WO 2017 / 005725 and has the following formula: N About About N H F About NH 2 Cl N About NNF F F CH 3 CH 3 Active ingredient (I) The active substance (I) acts as an inhibitor of factor XIa and, due to this specific mechanism of action, after oral administration is useful for the treatment and / or prevention of disorders, mainly thrombotic or thromboembolic disorders and / or thrombotic or thromboembolic complications, including cardiovascular vascular disorders, including coronary artery disease, angina pectoris, myocardial infarction, or stent thrombosis, and also disorders in the cerebrovascular arteries and other disorders leading to transient ischemic attacks (TIA), ischemic strokes, including cardioembolic and non-cardioembolic strokes, and / or disorders peripheral arteries, leading to peripheral arterial disease, including occlusion peripheral arteries, acute limb ischemia, amputations, reocclusions and restenosis after interventions such as angioplasty, stent implantation or bypass surgery, and / or stent thrombosis. To develop a solid dosage form for oral administration, active ingredient (I), (4S)-24-chloro-4- ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide, used in the form of amorphous form or crystalline modification I, or as a mixture of amorphous form and crystalline modification I. In case of diseases that require long-term treatment, or for long-term prevention of diseases It is recommended to keep the frequency of medication as low as possible and the size of the tablets as small as possible. This is not not only more convenient for the patient, but also increases the reliability of treatment by reducing the disadvantages of irregular (improve compliance). To increase compliance, especially in elderly patients, tablets should be as small as possible, i.e. have a high concentration of active substance, especially taking into account high dosages. During development, it was discovered that the active ingredient (I) is available in at least two solid forms, amorphous form and crystalline modification I. Also during development it was found that the relative bioavailability in rats is reduced to 11% upon administration of crystalline modification I of the active substance (I). In addition, the behavior dissolution of solid oral dosage forms is worse when solid oral dosage forms are oral administration, such as tablets, prepared by standard methods known to those skilled in the art industry, contain crystalline modification I of the active substance (I). In addition, the active substance (I) is available in two enantiomeric forms, of which one form is ineffective in-vivo. Thus, the goal of the development was to create solid dosage forms for oral administration, to which consist of (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)- pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active substance (I)), where solid The oral dosage form demonstrates better solubility and good bioavailability of the active ingredient. substance (I). In addition, the enantiomeric purity of the active substance (I) must be maintained not only in the solid dosage form, but also in the process of its production. It is necessary to achieve a high drug load (> 20% of active substance (I) per dosage form) to ensure a minimum tablet size. In addition, amorphous the form of the active substance (I) must be stable in solid dosage forms during long-term storage. Quite impressively, a solid dosage form consisting of an amorphous solid dispersion (ASD) in which the active substance (I) is present in amorphous form, exhibits excellent dissolution behavior and good bioavailability. In addition, the enantiomeric purity of the active substance (I) can be maintained not only in the amorphous solid dispersion (ASD), but also in solid dosage form, as well as in the process of obtaining this form by the method wet granulation, whereby a high drug load can be achieved (> 20% of active substance (I) The amorphous form of the active substance (I) is stabilized by excipients in the amorphous form. solid dispersion (ASD). Since the active substance (I) is not stabilized in a standard IR tablet, dissolution and bioavailability cannot be achieved with standard formulation approaches that do not inhibit crystallization of the amorphous active substance (I). Crystallization of the active substance (I) leads to a decrease in dissolution rate and bioavailability of the active substance (I). In addition, a production method with a combination of certain excipients and a combination of certain solvents allows to start a process for obtaining the active ingredient (I) in amorphous form and / or in crystalline modification I and to obtain a solid dosage form for oral administration consisting of the following components (4S)-24- chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole- 2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active substance (I)), where the amorphous form of the active substance (I) stabilized in an amorphous solid dispersion (ASD). In the context of the present invention, the term "amorphous solid dispersion" (ASD) is used, while in the literature some authors use the term "solid solution", which has the same meaning as solid dispersion in context of the present invention. Next, various types of solid dispersions (solid solutions, glass solutions, glass suspensions, amorphous precipitates in crystalline support, eutectic or monotectic, formation of compounds or complexes and their combinations) together called a solid dispersion. In the context of the present invention, the term "crystallization" means crystallization, since the active substance has previously was not crystalline, and / or recrystallization, since the active substance was crystalline, was then converted to an amorphous form, stabilized in the amorphous form and subsequently crystallized again. The "matrix" according to the present invention is polymeric excipients, non-polymeric excipients and their combinations capable of dissolving or dispersing the active ingredient (I). In the context of the present invention, "matrix" consists of a combination of a "solid dispersion base" and a "carrier" used in the process of obtaining amorphous solid dispersion (ASD). Thus, the "matrix" becomes an integral part of the amorphous solid dispersion (ASD). In the prior art, some authors use the term "carrier" instead of "matrix" or instead of "matrix agent". Amorphous solid dispersions (ASD) and methods for their preparation are known as such. C. Leuner and J. Dressman, Eur. J. Pharm. Biopharm., 50 (2000) 47-60, share methods for obtaining solid dispersions conditionally into hot melt methods and methods using solvents. According to C. Leuner and J. Dressman, the use of hot melt extrusion to obtain solid dispersions is considered as a method, which is the method of choice for obtaining solid dispersions. The authors prefer hot melt extrusion as a solvent-free method, since small changes in the conditions used to remove the solvent, can lead to quite significant changes in product characteristics. J. Breitenbach, Eur. J. Pharm. and Biopharm., 54 (2002) 107-117, classifies the most relevant technologies obtaining solid dispersions in hot spin mixing, introduction by spraying drying, co-evaporation, co-precipitation, freeze-drying and roller mixing or co-grinding. In general, methods based on solvent evaporation are known, for example, sublimation drying, spray drying, vacuum drying, layering of powders, granules or pellets and granulation in fluidized bed. J. Breitenbach states that solid dispersions exhibit different and mostly unpredictable behavior regarding, for example, chemical and physical stability. RJ Chokshi et al., J. Pharm. Sci., 97(6) (2008) 2286-2298 and GP Andrews et al., J. Pharm. Pharmacol. 10 62 (2010) 1580-1590, argue that solid dispersions are inherently unstable. Solid dispersion approaches to improving the dissolution of drugs involves the creation of a glass solution in which the drug is in a metastable amorphous state with high internal energy and specific volume. This causes the system to tend to crystallize during storage. Choosing the acquisition method and parameters to be used, as well as determining the appropriate auxiliary substances to avoid crystallization is also not obvious to a person skilled in the art. According to N. Shah et al., 2014, p. 130 (Fig. 4.2), various potential methods can be considered for the preparation of amorphous solid dispersions. excipients. Not all of these excipients are equally suitable for the preparation of amorphous solids dispersions. G. Van den Mooter, Drug Discovery Today: Technologies, vol. 9(2) (2012) e79-e85 describes the application and obtaining amorphous solid dispersions and notes that, despite enormous research efforts both in both in academia and in the pharmaceutical industry, very few products based on on the technology of obtaining solid dispersions. Problems of physical stability during the shelf life recognized as the main reason for this discrepancy. The so-called multicomponent solid dispersions, in which one or more drugs are dispersed in matrix (carrier), consisting of at least two compounds that have properties capable of modifying or improve the drug delivery system in terms of release, permeability, thermodynamic stability and thus affect bioavailability, described in the article by LM De Mohac, et al. in the Journal of Drug Delivery Science and Technology, 57 (2020) 101750. K. Six et al., J. Pharm. Sic., 93 (2004) 124-131 investigated solid dispersions of itraconazole in combination with two polymers (PVPVA64, a copolymer of N-vinylpyrrolidone and vinyl acetate, and Eudragit E100, an aminomethacrylate copolymer) and found that the stability and dissolution rate of solid dispersions consisting of combined polymers, surpass those that could be achieved using only one polymer. However, in the work of Y. Huang et al., Acta Pharmaceutica Sinica B, 4(1) (2014) 18-25 it is emphasized that The intermolecular interaction of a drug with a polymer has always been / is a determining factor in the development and characteristics of solid dispersions. The stability of solid dispersions is also affected by moisture absorption during storage. For example, polyvinylpyrrolidone (PVP) is known for its ability to absorb moisture, and polymers that are resistant to water absorption, such as hydroxypropyl methylcellulose acetate succinate (HPMCAS), has become the first choice for obtaining stable solid dispersions, as mentioned in the work of DT Friesen et al., Mol. Pharm., 5(6) (2008) 1003-1019. Depending on the drug substance-carrier combination, the release characteristics of the solid solution change, and therefore they are one of the main factors affecting the efficiency of solid dispersion. C. Leuner and J. Dressman, Eur. J. Pharm. Biopharm., 50 (2000) 47-60 emphasize that the drug substance-carrier ratio should be determined very carefully to find the optimal ratio for the formulation. The release rate can slow down with increasing amount of carrier. Depending on the carrier or carrier mixture, even gelation, which leads to a decrease in the release rate. Thus, it is not within the skill of the art to obvious which excipient to use or which technological process to use to obtain amorphous solid dispersions containing the active substance(I). Furthermore, WO2020 / 210629 describes an amorphous solid dispersion (ASD) containing a factor XIa inhibitor. (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)- 9-methyl-3,4,7,15-tetraazatricyclo [12,3,1,02,6] octadeca-1(18),2(6),4,14,16-pentaen-8-one. Compound formulated as an amorphous solid dispersion in pharmaceutically significant polymers such as hydroxypropylmethylcellulose acetate succinate (HPMCAS), by spray drying, and amorphous solid the dispersion has a drug load of less than 20% of the active substance (I) per dosage form. As mentioned above, the most common problems in preparing amorphous solid dispersion (ASD) are physical stability of the amorphous solid dispersion, type and amount of matrix, ratio of drug and matrix necessary to ensure the required increase in release rate, as well as the selection of the appropriate technological method of production and its scaling to ensure physical and chemical stability amorphous solid dispersion and the drug included therein. It has surprisingly been found that an amorphous solid dispersion (ASD) according to the present invention containing an active substance (I) with excellent dissolution behavior and good bioavailability of the active substance (I), as well as preserving the enantiomeric purity of the active substance (I), depends on a) the matrix used, b) the solvent, used in the technological process, and c) the technological process of production. Methods and auxiliary The substances selected for the present invention differ in some aspects from the methods and excipients, known to those skilled in the art, which are well known for obtaining an amorphous solid dispersion (ASD). a) matrix It was also unexpectedly discovered that the amorphous form of the active substance (I), incorporated into an amorphous solid dispersion according to the present invention can be stabilized by using only one polymer as matrix, which is also contrary to the prior art (K. Six et al., J. Pharm. Sic., 93 (2004) 124-131 and LM De Mohac, et al., Journal of Drug Delivery Science and Technology, 57 (2020) 101750), which prefers multicomponent systems containing at least two polymers as a matrix. Additionally, it was surprising that using polyvinylpyrrolidone (PVP) as a matrix polymer to obtain an amorphous solid dispersion containing the active ingredient (I) according to the present invention, in which the amorphous the form of the active substance (I) is stabilized not only during the technological method of obtaining, but also during long-term or open storage, unlike DT Friesen et al., where PVP is described as worse because of its water absorption. Surprisingly, hydroxypropyl methylcellulose acetate succinate (HPMCAS) is not resulted in the desired dissolution criteria (release of at least 85% of the active substance (I) into the medium release after a study period of 30 minutes) and may not stabilize the active substance (I) in its amorphous state form, which also contradicts DT Friesen et al. where HPMCAS is preferred over PVP. The advantage of the present invention is that the amorphous form of the active substance (I) can be stabilized in amorphous solid dispersion (ASD) by using polyvinylpyrrolidone (PVP) as the only polymer in the matrix, resulting in a solid pharmaceutical dosage form with a high drug load (> 20% of the active substance (I) per dosage form), which allows for small tablet sizes. b) solvent used in the technological process of obtaining Surprisingly, the combination of ethanol and acetone solvents allowed for a more than 5-fold increase in solubility compared to the solubility when using pure ethanol and increase the solubility by approximately 2 times compared to with solubility when using pure acetone. The solvent in the granulation method allows (4S)-24-chloro-4-ethyl- 73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide (active substance (I)) can be introduced into the process for obtaining amorphous solid dispersion (ASD) in the form of amorphous form or crystalline modification I, or as a mixture of both forms. c) technological method of obtaining It has surprisingly been found that an amorphous solid dispersion (ASD) according to the present invention containing an active substance (I) cannot be obtained by hot melt extrusion, as proposed and supported by C. Leuner and J. Dressman. The use of a solvent-free process, such as hot melt extrusion, resulted in the production of a racemic mixture of the active substance (I). Since only one enantiomer of the active substance (I) is effective in-vivo, after administration of an amorphous solid dispersion containing the active substance (I), obtained by hot melt extrusion, a decrease in bioavailability is observed in animals or humans. On In contrast to the prior art, an amorphous solid dispersion containing the active ingredient (I) according to the present invention, can be obtained by a wet granulation method, which ensures reproducible enantiomeric purity in each received batch. Amorphous solid dispersion (ASD) This invention provides an amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl-73-fluoro-35- methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix. This invention also provides an amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl-73-fluoro-35- methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix and sweeteners, flavors and colors as needed. The present invention also provides an amorphous solid dispersion (ASD) in which (4S)-24-chloro-4-ethyl-73-fluoro-35- methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- Dibenzeneheptaphane-74-carboxamide (active ingredient (I)) is present in amorphous form. In the context of the present invention, a pharmaceutically acceptable matrix consists of a combination of a solid dispersion base and carrier. In the context of the present invention, the solid dispersion base is a pharmaceutically acceptable polymer, selected from the group consisting of polyethylene oxide, polyvinylpyrrolidone (PVP), copolymer vinylpyrrolidone / vinyl acetate (copovidone) (e.g. Kollidon VA64), polyalkylene glycol (e.g. polyethylene glycol), hydroxyalkylcelluloses (e.g. hydroxypropylcellulose), hydroxyalkylmethylcellulose (e.g. hydroxypropylmethylcellulose), carboxymethylcellulose, sodium carboxymethylcellulose, polymethacrylates (e.g., Eudragit® type), polyvinyl alcohol, polyvinyl acetate, vinyl alcohol / vinyl acetate copolymer and combinations thereof. Preferably solid dispersion the base is selected from the group consisting of polyvinylpyrrolidone (PVP), vinylpyrrolidone / vinyl acetate copolymer (copovidone), hydroxypropylcellulose, hydroxypropylmethylcellulose, polyethylene glycol and polyethylene oxide. The most preferred solid dispersion base is the polymer polyvinylpyrrolidone (PVP). In the context of the present invention, the carrier is selected from the groups of fillers, lubricants, disintegration promoters, surfactants, sweeteners, flavors and / or colors or combinations thereof. (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)- [1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) and solid dispersion base present in the amorphous solid dispersion (ASD) in the ratio of active substance (I) to solid dispersion base from 1 to 0.5 to 1 to 20. The preferred ratio of active substance (I) to solid dispersion is base from 1 to 0.5 to 1 to 10, even more preferably the ratio of active substance (I) to solid dispersion base from 1 to 0. From 1:5 to 1:5 and very preferred is the ratio of active substance (I) to solid dispersion base 1:2, especially the ratio of active substance (I) to solid dispersion base 1:2 allows for a high drug load and small tablet sizes. The drug loading of the active substance (I) in the amorphous solid dispersion (ASD) is > 20%, and the desired the drug load in the amorphous solid dispersion (ASD) is ≥ 25%. (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)- [1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) and the carrier are present in an amorphous solid dispersion (ASD) in a ratio of active ingredient (I) to carrier from 1 to 0 to 1 to 20. Preferred is the ratio of active substance (I) to carrier is from 1 to 0 to 1 to 5 and the ratio of active substance (I) to carrier is very preferred of substance (I) to carrier 1 to 1. This means that the matrix may also be devoid of carrier. Solid pharmaceutical dosage forms This invention provides a solid pharmaceutical dosage form for oral administration that consists of an amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo- 14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix. This invention provides a solid pharmaceutical dosage form for oral administration that consists of an amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo- 14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix and, if necessary, sweeteners, flavors and dyes. This invention provides a solid pharmaceutical dosage form for oral administration that consists of an amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo- 14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix, and other pharmaceutically acceptable excipients substances. This invention provides a solid pharmaceutical dosage form for oral administration that consists of an amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo- 14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix and, if necessary, sweeteners, flavors and dyes, and other pharmaceutically acceptable excipients. This invention also provides solid pharmaceutical dosage forms for oral administration that contain a) amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14- (trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix, b) at least one lubricant, c) at least one disintegration promoter, d) if necessary, one or more fillers, and e) if necessary, one or more surfactants. Furthermore, the present invention provides solid pharmaceutical dosage forms for oral administration, containing a) amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14- (trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix, b) at least one lubricant, c) at least one disintegration promoter, d) if necessary, one or more fillers, and e) if necessary, one or more surfactants, where at least 85% of the active substance (I) is released into the release medium after 30 minutes, respectively to the European Pharmacopoeia isolation method using apparatus 2 (paddle). For oral administration, an amorphous solid dispersion containing the active ingredient (I) can be formed into solid or liquid preparations such as powder, granules, pellets, tablets, sachets, capsules, dragees, chewable tablets, effervescent tablets, dispersible tablets, lozenges, lozenges, melts, solutions, suspensions or emulsion, and can be obtained according to methods known in the art for obtaining pharmaceutical compositions. The pharmaceutical dosage form according to the present invention is a tablet. The pharmaceutical dosage form according to the present invention is an immediate-dissolving tablet. The pharmaceutical dosage form according to the present invention is a tablet, optionally coated coated, preferably a tablet coated with a film. The drug load of the active substance (I) in the tablet is > 20%, and the drug load is mainly the loading in the tablet is ≥ 23%. The pharmaceutical dosage form according to the present invention is also an amorphous solid dispersion. (ASD) containing the active substance (I) in a matrix and, if necessary, sweeteners, flavors and colorants, formed into sachets. (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)- [1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) is present in the tablet in in an amount of from 2 mg to 100 mg, preferably in an amount of from 5 mg to 50 mg, also preferably in an amount of from 20 mg to 50 mg, even more preferably in an amount of 50 mg. It is expected that a solid dosage form, especially in the form of a tablet, as well as granules of an amorphous solid dispersions (ASD) will be stable when stored for a long period of time, preferably long-term stable. Solid dosage form, especially in tablet form, as well as amorphous solid dispersion (ASD) granules are stable on storage for at least 3 months, more preferably for at least 6 months, more preferably for at least 12 months, more preferably for at least 24 months, more preferably for at least 30 months and most preferably for at least 48 months. Long-term storage means storage for more than 24 months. Stable storage means storage with degradation of the active substance (I) by no more than 10%, mainly with degradation of the active substance (I) by no more than 3% and with preservation of the amorphous form of the active substance (I). Storage conditions for stability assessment, e.g. closed container at 25 °C / 60 % relative humidity or closed container at 30 °C / 75 % relative humidity or open container at 25 °C / 60 % relative humidity humidity or open container at 40 °C / 75 % relative humidity (stress conditions). Surprisingly excellent stability of the solid dosage form containing the active substance (I), even in stressful conditions conditions (open storage at 40 °C and 75% relative humidity for 6 months), allows the use of unprotected packaging (e.g. HPDE bottles without desiccant) for the dosage form of the active substance (I). In the context of the present invention, immediate-dissolving tablets are, in particular, tablets that release at least 85% of the active substance (I) into the dissolution medium after 30 minutes, according to the method dissolution according to the European Pharmacopoeia using device 2 (blades). Stirrer rotation speed is 75 rpm (revolutions per minute) in 900 ml of dissolution medium. According to the present invention, the release medium is acetate buffer pH 4.5 + 0.1% SDS or + 0.15% SDS, or + 0.2% SDS, or + 0.3% SDS, or 0.01 M hydrochloric acid + 0.1% SDS or + 0.2% SDS. SDS is an abbreviation for for sodium dodecyl sulfate, also called sodium lauryl sulfate. This invention also relates to the use of (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14- (trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (I) to obtain a solid pharmaceutical dosage form for oral administration according to the invention. The active substance (I) is present in the pharmaceutical dosage forms of the invention in amorphous form. The present invention provides solid pharmaceutical dosage forms in which the amorphous solid dispersion is essentially homogeneous. In the context of the present invention, "excipients" are fillers, lubricants, disintegrants, surfactants, sweeteners, flavors and colors. Therefore, it may happen that a specialist in This field will assign similar or even identical substances to more than one of the above groups of substances. However, in the context of this invention, the functional descriptions of substances are intentionally filled with specific substances, to clarify the relevant properties assigned to them. The term "pharmaceutically acceptable" refers to those excipients which, within the limits of reasonable medical practice, conclusion, suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reaction or other problems or complications commensurate with a reasonable proportion benefit / risk. The fillers that can be used in the composition according to the present invention are selected from the list given below. consists of cellulose powder, microcrystalline cellulose, silicified microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, magnesium trisilicate, mannitol, maltitol, sorbitol, xylitol, lactose (anhydrous or in the form of a hydrate, e.g. monohydrate), dextrose, maltose, sucrose, glucose, fructose or maltodextrins. The preferred filler is microcrystalline cellulose or lactose or a combination thereof. Very It is preferable that no filler is used. Lubricants prevent ingredients from sticking, for example to production equipment. Lubricants that can be used in the composition according to the present invention are selected from the list below. consists of magnesium stearate, sodium stearyl fumarate, stearic acid, glycerol monostearate, glycerol monobehenate, calcium behenate, hydrogenated vegetable fat or oil, polyethylene glycol and talc. Preferred lubricants according to the present invention are those selected from the list consisting of of magnesium stearate, stearic acid and talc. Magnesium stearate is highly preferred as a lubricant. Disintegration promoters expand and dissolve when wet. They can be used for the breakdown of the dosage form in the digestive tract, releasing the active substances. Disintegration promoters, suitable in the context of the present invention are those selected from the list consisting of alginic acid, cross-linked polyvinylpyrrolidone, corn starch, modified starch and starch derivatives such as sodium carboxymethyl starch, cellulose derivatives such as carmellose calcium (calcium carboxymethylcellulose) and croscarmellose sodium (crosslinked polymer of sodium carboxymethylcellulose) or microcrystalline cellulose, or a combination of croscarmellose sodium and microcrystalline cellulose. As a disintegration promoter, it is best suited croscarmellose sodium or crosslinked polyvinylpyrrolidone. A highly preferred disintegration promoter is croscarmellose sodium. Surfactants are usually organic compounds that are amphiphilic, i.e. contain both hydrophobic groups (their tails) and hydrophilic groups (their heads). Thus, a surfactant contains both a water-insoluble (or oil-soluble) component and a water-soluble component and contributes to dissolution of certain chemical compounds. The surfactants according to the present invention are complexing agents such as cyclodextrins and sodium ethylenediaminetetraacetic acid (EDTA), co-solvents such as ethanol, propylene glycol and dimethylacetamide, surfactants such as fatty alcohols (e.g. cetyl alcohol), phospholipids (e.g. lecithin), bile acids, polyoxyethylene stearate fatty esters (e.g. polyoxyethylene), polyoxyethylene sorbitan fatty esters, polyoxypropylene- polyoxyethylene- block copolymers (e.g. poloxamer), alkyl sulfates (e.g. sodium lauryl sulfate, sodium cetyl stearyl sulfate), alkyl soaps (e.g. sodium palmitate, sodium stearate) and fatty acid esters sucrose acids. Sodium lauryl sulfate is the best surfactant. A pharmaceutically acceptable excipient that has a taste is best suited as a sweetener. similar to sugar. Sweeteners suitable in the context of the present invention are those selected from the list that consists of sucrose, saccharin, sodium, potassium or calcium saccharin, acesulfame potassium, neotame, alitame, glycyrrhizin or thaumatin, or sugars such as glucose, mannitol, fructose, sucrose, maltose, maltitol, galactose, sorbitol or xylitol. In the context of the present invention, sweeteners are added in amounts known to those skilled in the art. this industry. In the context of the present invention, flavorings are pharmaceutically acceptable excipients, suitable for improving or imparting a pleasant taste to a pharmaceutical dosage form to complement it action, as well as to enhance its elegance. In the context of the present invention, flavorings are natural flavourings obtained from vegetable or animal raw materials, identical to natural flavourings obtained by synthesis or isolated by chemical processes that are chemically and organoleptically identical flavourings naturally present in products intended for human consumption, as well as artificial Flavorings. In the context of the present invention, flavorings are added in amounts known to those skilled in the art. Flavoring agents suitable in the context of the present invention are those selected from the list consisting of synthetic / artificial flavors such as amyl acetate (banana flavor), benzaldehyde (cherry flavor), or almond flavor), ethyl butyrate (pineapple flavor), methyl anthranilate (grape flavoring), natural flavorings such as essential oils and resins, herbs and spices, and identical natural flavors, which are aromatic substances obtained by synthesis or isolated by through chemical processes, and whose chemical composition is identical to their natural counterpart. In the context of this of the invention, flavorings are added in amounts known to those skilled in the art. In the context of the present invention, colorants are pharmaceutically acceptable excipients suitable for to color a colorless dosage form or to enhance its color, to minimize batch-to-batch variations series or to replace an existing color to complement its effect, as well as to enhance it elegance. These can be any dyes, lakes or pigments such as indigo carmine, riboflavin and dioxide titanium. In the context of the present invention, dyes are added in amounts known to those skilled in the art. In the context of the present invention, optional coating is performed with the addition of conventional coating and film-forming agents known to those skilled in the art, such as hydroxypropylcellulose, hydroxypropylmethylcellulose (hypromellose), ethylcellulose, polyvinylpyrrolidone, vinylpyrrolidonevinyl acetate copolymers (e.g. Kollidon® VA64, BASF), shellac, copolymers of acrylic and / or methacrylic esters acids with trimethylammonium methylacrylate, copolymers of dimethylaminomethacrylic acid and neutral esters of methacrylic acid, polymers of methacrylic acid or esters of methacrylic acid, ethyl acrylate- methyl methacrylate copolymers, methacrylic acid and methyl acrylate copolymers, propylene glycol, polyethylene glycol (e.g. polyethylene glycol 3350), glycerol triacetate or triethyl citrate and / or dyes / pigments such as titanium dioxide, iron oxide (e.g. red iron oxide, yellow iron oxide), indigotine or corresponding colored lakes, and / or anti-caking agents such as talc, and / or light-reducing agents such as titanium dioxide. As optional coating and film-forming agents according to the present invention are preferred hypromellose and polyethylene glycol, as Red iron oxide is preferred as a dye, and iron dioxide is preferred as a suppressant titanium. The coating mixture mentioned in this document can also be used as a ready-to-use a coating system such as that commercially available under the trade name Opadry® is used. Opadry 14F94373® is a mixture of approximately 60 wt. % hydroxypropylmethylcellulose, approximately 19.4 wt. % titanium dioxide, about 0.6 wt. % red iron oxide and about 20 wt. % polyethylene glycol. Preference is given to ready-to-use coating system under the trade name Opadry®. Preferably, the coating comprises from about 0.5% to 10% by weight of the tablet composition coated. coating, preferably from 0.5% to 4.5% by weight of the tablet composition, more preferably from about 1.5% to 4.5% by weight of the film-coated tablet composition. In the comparative compositions according to the invention, binders are used. Binders, which can be used are cellulose powder, microcrystalline cellulose, silicified microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, magnesium trisilicate, mannitol, maltitol, sorbitol, xylitol, lactose (anhydrous or in the form of a hydrate, e.g. monohydrate), dextrose, maltose, sucrose, glucose, fructose, maltodextrins or hypromellose (e.g. hypromellose 3 cP). Preferred as a binder is hypromellose (e.g. hypromellose 3 cP). Method for obtaining amorphous solid dispersion (ASD) This invention provides a method for preparing an amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl- 73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide (active substance (I)), characterized in that an amorphous solid dispersion (ASD) is obtained by wet granulation. This invention provides a method for preparing an amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl- 73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide (active substance (I)), characterized in that an amorphous solid dispersion (ASD) is obtained by granulation in a pseudo fluidized bed. Wet granulation can be carried out in a mixer, spray dryer or granulator. fluidized bed. Wet granulation in a fluidized bed granulator (= granulation in fluidized bed) is preferred. In wet granulation, the active ingredient (I) is dissolved in the granulating liquid and introduced into the granulator. fluidized bed. Most preferably, the granulating liquid containing the active ingredient (I) is sprayed onto a carrier by fluidized bed granulation. In the context of the present invention, the granulating liquid consists of a solid dispersion base and solvents. Solvents suitable for obtaining amorphous solid dispersions using methods solvent evaporation, such as fluidized bed granulation, can be any solvents, in in which the active ingredient (I) can be dissolved. The polymer base of the solid dispersion must also be sufficiently soluble to make the process practical. The best solvents are alcohols (e.g. methanol, ethanol, n-propanol, isopropanol and butanol), ketones (e.g. acetone, methyl ethyl ketone and methyl isobutyl ketone), esters (e.g. ethyl acetate and propyl acetate) and various other solvents such as acetonitrile, methylene chloride, chloroform, hexane, toluene, tetrahydrofuran, cyclic ethers and 1,1,1-trichloroethane. Can also be used solvents with less volatility, such as dimethylacetamide or dimethyl sulfoxide. The best solvents are for obtaining amorphous solid dispersions containing the active substance (I) are methanol, ethanol, n-propanol, isopropanol, acetone or mixtures thereof. Also preferred for the preparation of amorphous solid dispersions, which containing the active ingredient (I), is ethanol or a mixture of 20% ethanol and 80% acetone, or 50% ethanol and 50% acetone. Very preferably for obtaining amorphous solid dispersions containing the active ingredient (I) in the form of a mixture 50% ethanol and 50% acetone. This invention provides a method for preparing an amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl- 73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide (active substance (I)), characterized in that an amorphous solid dispersion (ASD) is obtained by granulation in a fluidized bed, in which the active substance (I) is dissolved in granulating liquid and is introduced into the fluidized bed granulator. This invention provides a method for preparing an amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl- 73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide (active substance (I)), characterized in that an amorphous solid dispersion (ASD) is obtained by granulation in a fluidized bed in which the active substance (I) is dissolved in granulating liquid, which contains a mixture of 50% ethanol and 50% acetone, and is introduced into a fluidized bed granulator layer. Amorphous solid dispersion (ASD) is preferably produced in the form of granules. This invention provides a method for preparing an amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl- 73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide (active substance (I)), characterized by the fact that a) (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)- [1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active substance (I)) is dissolved in the corresponding solvent or mixture of solvents, b) a polymer (solid dispersion base) is added to obtain a granulation liquid, c) the granulation liquid is sprayed onto the carrier, d) the solvent or solvents evaporate to form a granulate. In an additional step e) the granulate obtained in step d) is optionally further treated by mixing with sweeteners, flavors and colors, and / or grinding, and / or sieving, and / or compaction to obtain a granulate which can be used as a solid pharmaceutical dosage form form. Amorphous solid dispersion (ASD) contains (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14- (trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) is produced by one of the above methods. Amorphous solid dispersion (ASD) contains (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14- (trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) obtained by one of the above-mentioned methods. Method for obtaining solid dosage forms for pharmaceutical preparations This invention provides a method for preparing solid pharmaceutical dosage forms for oral administration. applications containing amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl-7-3-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphan-74- carboxamide (active substance (I)), characterized by the fact that a) amorphous solid dispersion (ASD) consisting of (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14- (trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix, is first prepared, b) and amorphous solid dispersion (ASD), optionally with the addition of pharmaceutically acceptable excipients substances, then converted into a pharmaceutical dosage form. In addition, this invention provides a method for preparing solid pharmaceutical dosage forms for oral administration containing amorphous solid dispersion (ASD) contains (4S)-24-chloro-4-ethyl-73-fluoro-35- methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide (active substance (I)), characterized by the fact that a) amorphous solid dispersion (ASD) consisting of (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14- (trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix, is first prepared, b) and amorphous solid dispersion (ASD), optionally with the addition of pharmaceutically acceptable excipients substances, then converted into a pharmaceutical dosage form, wherein at least 85% of the active substance (I) is released into the release medium after 30 minutes, according to the European Pharmacopoeia detection method using apparatus 2 (paddle). In addition, this invention provides a method for preparing solid pharmaceutical dosage forms for oral administration containing amorphous solid dispersion (ASD) contains (4S)-24-chloro-4-ethyl-73-fluoro-35- methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide (active substance (I)), characterized by the fact that a) amorphous solid dispersion (ASD) consisting of (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14- (trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix, prepared by wet granulation, b) and amorphous solid dispersion (ASD), optionally with the addition of pharmaceutically acceptable excipients substances, then converted into a pharmaceutical dosage form. The solvent in the granulation process to obtain an amorphous solid dispersion (ASD) allows (4S)-24-chloro- 4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazol- 2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) can be introduced into the process for obtaining solid dosage forms in the form of amorphous form or crystalline modification I, or in the form of a mixture of both forms. The conversion into a dosage form in step (b) includes, for example, tabletting, capsule filling, preferably hard gelatin capsules, or sachet-like fillings, in each case according to conventional methods known to those skilled in the art, if necessary with the addition of other pharmaceutically acceptable excipients. For conversion into a solid dosage form in step (b) the amorphous solid dispersion, which is isolated in the form of granulate, can be pressed with rollers and ground with or without additional excipients to obtain roller-pressed granulate. The resulting granulate with additional excipients or without them compressed into a pharmaceutical dosage form, such as tablets. In addition, this invention provides a method for preparing solid pharmaceutical dosage forms for oral administration containing amorphous solid dispersion (ASD) contains (4S)-24-chloro-4-ethyl-73-fluoro-35- methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide (active substance (I)), characterized by the fact that a) amorphous solid dispersion (ASD) consisting of (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14- (trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix, prepared by wet granulation, b) other pharmaceutically acceptable excipients are added to the amorphous solid dispersion (ASD), c) the resulting mixture is compressed into tablets, and d) the tablets are additionally coated to obtain a dosage form. In addition, this invention provides a method for preparing solid pharmaceutical dosage forms for oral administration containing amorphous solid dispersion (ASD) contains (4S)-24-chloro-4-ethyl-73-fluoro-35- methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide (Active substance (I)), characterized by the fact that a) amorphous solid dispersion (ASD) consisting of (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14- (trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (Active ingredient (I)) in a pharmaceutically acceptable matrix, prepared by wet granulation, b) other pharmaceutically acceptable excipients are added to the amorphous solid dispersion (ASD), c) the resulting mixture is compacted with rollers and, if necessary, crushed, d) other pharmaceutically acceptable excipients are added if necessary, e) the resulting mixture is compressed into tablets, and f) the tablets are additionally coated to obtain a dosage form. Solid dosage forms for oral administration containing amorphous solid dispersion (ASD) contains (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)- [1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) is produced by one of the above methods. Solid dosage forms for oral administration containing amorphous solid dispersion (ASD) contains (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)- [1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active substance (I)) was obtained by one of the above-mentioned methods. Medicines and their uses Use of a solid dosage form for oral administration containing an amorphous solid a dispersion of amorphous active substance (I), stabilized with selected excipients and prepared in a manner that ensures enantiomeric purity, results in high relative bioavailability in humans in range from 85% to even 100%, preferably from 88% to even 100%. This invention also provides medicaments comprising a solid pharmaceutical dosage form for for oral administration according to the invention, which contains the active ingredient (I). This invention also relates to the use of solid dosage forms for oral administration according to invention, containing the active ingredient (I), and obtaining a medicinal product for the treatment and / or prevention disorders, mainly thrombotic or thromboembolic disorders and / or thrombotic or thromboembolic complications, particularly cardiovascular disorders, including coronary heart disease, angina, heart attack myocardial or stent thrombosis, as well as disorders related to cardiovascular disease, and disorders in the cerebrovascular arteries and other disorders leading to transient ischemic attacks (TIA), ischemic strokes, including cardioembolic and non-cardioembolic strokes, and / or disorders peripheral arteries, leading to peripheral arterial disease, including occlusion peripheral arteries, acute limb ischemia, amputation, reocclusions and restenosis after interventions such as angioplasty, stent implantation, bypass surgery, and / or stent thrombosis. This invention also relates to the use of solid pharmaceutical dosage forms for oral administration. uses according to the invention, containing active ingredient (I), for prophylaxis, secondary prophylaxis and / or treatment of disorders, in particular myocardial infarction, ischemic strokes, including cardioembolic and non-cardioembolic strokes, acute limb ischemia, reocclusions and restenosis after interventions such as angioplasty, stent implantation or bypass surgery, and / or stent thrombosis. The invention is illustrated in detail below by preferred working examples; however, the invention is not limited thereto. these examples. Unless otherwise stated, all amounts given are in mg of the dosage form. Experimental part Abbreviation: PXRD: Powder X-ray Diffraction IR tablet: immediate release tablet rel. BA: relative bioavailability AUC / D: area under the curve per dose Cmax / D: maximum concentration per dose HPMCAS MG: AquaSolve™ Hydroxypropylmethylcellulose Acetate Succinate Typ MG SDS: Sodium dodecyl sulfate, also known as sodium lauryl sulfate rh: relative humidity initial: earliest point of analysis after manufacture Active substance (I) crystalline means Active substance (I) in crystalline modification I. If with respect to the conditions If the storage is not indicated as "open" or "closed", then closed storage is meant. 1. Preparation of the active substance (I) 1.1 Obtaining the active substance (I) in amorphous form The active substance (I) is (4S)-24-chloro-4-ethyl-7-3-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H- 6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide, also known as 4- ({(2S)-2-[4-{5-chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridine-1(2H)- [(1,2-[(2,3-[(1,4 Example 235 in amorphous form. 1.2 Obtaining the active substance (I) in crystalline modification I The active substance (I) in crystalline modification I can be obtained by dissolving the active substance (I) in amorphous form in an inert solvent and crystallization of the active substance (I) in crystalline modification I with by adding the starting compound of formula (II) in crystalline modification A. The solubility of the active substance (I) in crystalline modification I in ethanol is approximately 35 mg / ml, in in acetone - approximately 80 mg / ml and in a mixture of ethanol / acetone (1:1) - approximately 180 mg / ml. 1,2,1 Preparation of 4-({(2S)-2-[4-{3-chloro-2-fluoro-6-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2- oxopyridin-1(2H)-yl]propanoyl}amino)-2-fluoro-benzamide (compound of formula (II)) 1,2,1,1 1-(2-Bromo-4-chloro-3-fluorophenyl)-4-(trifluoromethyl)-1H-1,2,3-triazole BrCl N NNF F F F 1-(2-Bromo-4-chloro-3-fluorophenyl)-4-(trifluoromethyl)-1H-1,2,3-triazole is synthesized starting from 2-bromo-4-chloro- 3-fluoroaniline (WO 2016 / 168098, pp. 59-60), first generating the azide derivative (in the presence of tert-butyl nitrite and trimethylsilyl azide, analogously to the synthesis of example 2,18A, WO 2017 / 005725, pp. 92-93), and then carrying out cycloaddition of an azide derivative with trifluoropropyne (in the presence of copper(I) oxide, analogous to the synthesis example 2,26A, WO 2017 / 005725, page 102). 1,2,1,2 4-{3-chloro-2-fluoro-6-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-2,5-dimethoxy-pyridine N About Cl N About NNF F F CH 3 F CH 3 A mixture of 1-(2-Bromo-4-chloro-3-fluorophenyl)-4-(trifluoromethyl)-1H-1,2,3-triazole (982 mg, 2.85 mmol), (2,5- dimethoxypyridin-4-yl)boronic acid (WO 2019 / 175043, page 23-24) (626 mg, 3.42 mmol, 1.2 equiv.) and potassium carbonate (1.18 g, 8.55 mmol, 3.0 equiv.) was dissolved in 1,4-dioxane (50 mL) and flushed with argon for 10 min, then the monodichloromethane adduct of [1,1-bis(diphenylphosphino)ferrocene]palladium(II) chloride (233 mg, 0.29 mmol, 0.1 equiv.). The reaction mixture was stirred at 100 °C (the oil bath was already preheated to 100 °C) overnight. Additional (2,5-dimethoxypyridin-4-yl)boronic acid (209 mg, 1.14 mmol, 0.4 equiv.) and monodichloromethane adduct of [1,1-bis(diphenylphosphino)ferrocene]palladium(II) chloride (116 mg, 0.14 mmol, 0.05 equiv.). The reaction mixture was stirred at 100 °C for an additional 5 h, left at RT for starting material and filtered through Celite®, which was washed with 1,4-dioxane. The combined filtrates were concentrated at under reduced pressure. The residue was purified by chromatography (silica gel, eluent: cyclohexane / ethyl acetate gradient). Yield: 432 mg (38% of theory). LC-MS (method 2): Rt=2.13 min; MS (ESIpos): m / z = 403 [M+H]+ ¹H-NMR (400 MHz, DMSO-d6): δ [m. h.] = 9.17 / 9.16 (2x s, 1H), 8.03 / 8.01 (2x d, 1H), 7.86 (s, 1H), 7.75 / 7.75 (2x d, 1H), 6.82 (s, 1H), 3.79 (s, 3H), 3.54 (s, 3H). 1,2,1,3 4-{3-chloro-2-fluoro-6-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-pyridin-2(1H)-one NH About Cl N About NNF F F CH 3 F Pyridine hydrobromide (429 mg, 2.68 mmol, 2.5 equiv.) was added to a solution of 4-{3-chloro-2-fluoro-6-[4- (trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-2,5-dimethoxypyridine (432 mg, 1.07 mmol) in N,N- dimethylformamide (10 mL). The mixture was stirred at 100 °C overnight and concentrated under reduced pressure. The residue was dissolved in water. After addition of ethyl acetate and phase separation, the aqueous phase was extracted twice. The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated. under reduced pressure. The residue was purified by chromatography (silica gel, eluent: dichloromethane / methanol gradient). Yield: 285 mg (68% of theory). LC-MS (method 2): Rt=1.46 min; MS (ESIpos): m / z = 389 [M+H]+ ¹H-NMR (600 MHz, DMSO-d6): δ [m. h.] = 11.3 (w s, 1H), 9.23 (s, 1H), 8.10-7.99 (m, 1H), 7.77 (m, 1H), 7.15 (s, 1H), 6.41 (s, 1H), 3.45 (s, 3H). 1,2,1,4 4-({(2S)-2-[4-{3-chloro-2-fluoro-6-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2- oxopyridin-1(2H)-yl]propanoyl}amino)-2-fluorobenzamide (compound of formula (II)) N About About N H CH 3 F About NH 2 Cl N About NNF F F CH 3 F 1,1,3,3-Tetramethylguanidine (420 μL, 3.35 mmol, 3.0 equiv.) was added under argon at RT to a solution of 4- {3-chloro-2-fluoro-6-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxypyridin-2(1H) one (438 mg, 1.12 mmol) in 2-propanol / acetone (4:1, 7.5 mL). The mixture was stirred at RT for 15 min, after which 4-{[(2R)-2- bromopropanoyl]amino}-2-fluorobenzamide (WO 2020 / 127504, example 1,19A, page 76) (355 mg, 1.23 mmol, 1.1 equiv.) and then 2-propanol / acetone (4:1, 7.5 mL). The reaction mixture was stirred at RT overnight and concentrated under reduced pressure. The residue was purified by chromatography (silica gel, eluent: gradient dichloromethane / methanol) and preparative HPLC (reversed phase, eluent: acetonitrile / water gradient). Yield: 539 mg (81% of theory). LC-MS (method 2): Rt=1.65 min; MS (ESIpos): m / z = 597 [M+H]+ ¹H-NMR (500 MHz, DMSO-d6): δ [m. h.] = 10.72 / 10.63 (2x s, 1H), 9.24 / 9.13 (2x s, 1H), 8.06-7.99 (m, 1H), 7.79- 7.74 (m, 1H), 7.72-7.60 (m, 2H), 7.56-7.48 (m, 2H), 7.38-7.32 (m, 1H), 7.27 / 7.25 (2x s, 1H), 6.48 / 6.47 (2x s, 1H), 5.51- 5.44 (m, 1H), 3.47 / 3.45 (2x s, 3H), 1.65 / 1.64 (2x s, 3H). 1,2,2 Preparation of the compound of formula (II) in crystalline modification A 306 mg of the compound of formula (II) in amorphous form was dissolved in 20 ml of a mixture of 50 vol.-% ethanol and 50 vol.-% water at room temperature. The solution was stirred for 24 hours at room temperature, resulting in the precipitation of white precipitate. The solvent was evaporated on a rotary evaporator. The resulting precipitate was dried in a vacuum drying oven. in a refrigerator at 40 °C for 16 hours. 273 mg of the compound of formula (II) in crystalline modification A was obtained. 1,2,3 Obtaining the active substance (I) in crystalline modification I 30 mg of the active substance (I) in amorphous form was dissolved in 2 ml of ethanol at room temperature. To 660 μl of water was added dropwise to the solution until the solution became cloudy. Then 1 mg of crystalline modification A of the compound of formula (II). Shortly after the addition, further fine precipitates were observed particles, but these particles quickly disappeared upon stirring, resulting in the formation of a transparent-looking solution. After stirring at room temperature for 48 hours, a suspension was obtained. The solid The material was filtered under vacuum and dried overnight at room temperature. The XRPD spectrum of the obtained of the solid corresponds to the crystalline modification I of the active substance (I). 1H-NMR analysis of the obtained solid indicates that the solid contains approximately 5 wt. % of the compound of formula (II). 1,2,4 Obtaining the active substance (I) in crystalline modification I in the form of pure active substance (I) 20.0 g of the active substance (I) in amorphous form was dissolved in a mixture of 40.0 g of propan-2-ol and 10.0 g of acetone at The mixture was heated to 60 °C and 126.0 g of water was added to the resulting solution over 60 minutes. 100.0 mg of crystalline modification I of the active substance (I) was added to the resulting mixture and stirred at 60 °C for 3 hours. Then another 4.8 g of active substance (I) in amorphous form was added and the mixture was stirred at 60 °C overnight. The resulting suspension was cooled to 20 °C over 60 minutes and stirred at 20 °C for 90 minutes. The suspension thus obtained was filtered under vacuum, washed twice with 42.5 g of of a mixture of propan-2-ol:acetone:water in a mass ratio of 4:1:12 and dried in vacuum at 40 °C. Yield: 22.4 g (90.3% of theoretical yield) of a pale white solid. 2. Isolation / dissolution method According to the European Pharmacopoeia, 10th edition, latest revision of the monograph 01 / 2016, solid The oral dosage form is tested using apparatus 2 (paddle). Speed The stirrer rotation is 75 rpm (revolutions per minute) in 900 ml of the medium specified below. Criterion The release is considered complete if all 6 test samples have released at least 85% of the active substance. substance (I) into the release medium after a study period of 30 minutes. Intermediate level Used for examples Acetate buffer pH 4.5+0.1% SDS 3-1 to 3-9 and 4-1 to 4-3 Acetate buffer pH 4.5+0.2% SDS 4-7, 4-8, 4-10, 4-11 and 4-13 Acetate buffer pH 4.5+0.3% SDS 4-4 to 4-6, 4-9, 4-12 and 4-14 to 4-18 Acetate buffer pH 4.5+0.15% SDS 4-14* 0.01 M hydrochloric acid + 0.1% SDS 2-1 and 2-3 0.01 M hydrochloric acid + 0.2% SDS 2-2 * samples of resistance 3. Method of obtaining liquid preparations Example 1-1 (comparative example) Mix tylose and water while stirring. Add active ingredient (I) in crystalline modification I and continue stirring. Example 1-2 (comparative example) The polyethylene glycol (PEG) solution is prepared by dissolving the active ingredient (I) in amorphous form in ethanol before adding PEG. Add water and mix the solution well. 4. Method for producing granulate in a fluidized bed Examples 2-1, 2-2 and 2-3 (comparison tablets) The binder and surfactant are dissolved in water, and the active ingredient (I) is suspended in this solution. In the fluidized bed granulation process, this suspension is sprayed as a granulation liquid onto the initial charge consisting of fillers and parts of the disintegration promoter. After drying and sieving The remaining disintegration promoter and lubricant, which is also a stearate if necessary, are added to the resulting granules. magnesium, and mixed. The mixture thus obtained ready for pressing is pressed to obtain tablets. The tablets are then coated with pigments, which are suspended in an aqueous solution consisting of coating and film-forming substances. Example 3-1 (Amorphous Solid Dispersion (ASD)) The solid dispersion base and the active ingredient (I) are dissolved in an organic solvent. In the process In fluidized bed granulation, this solution is sprayed as a granulating liquid onto the starting charge, which consists of a filler and a disintegration promoter (carrier). After drying and sieving, granulate is obtained. Organic solvents can be ethanol, acetone or combinations thereof. Examples 3-2, 3-3, 3-4, 3-5, 3-6, 3-7, 3-8 and 3-9 (Amorphous Solid Dispersion (ASD)) The solid dispersion base and the active ingredient (I) are dissolved in an organic solvent. In the process fluidized bed granulation this solution is sprayed as a granulating liquid onto the initial charge disintegration promoter (carrier). After drying and sieving, granulate is obtained. Organic solvents can be ethanol, acetone or combinations thereof. Example 4-1 (Drug form (tablet) containing amorphous solid dispersion (ASD)) The granulate obtained in Example 3-1 is mixed with fillers and a surfactant. This The mixture is pressed and crushed in rollers, followed by the addition and mixing of lubricant. The resulting The ready-to-press mixture is then pressed to produce tablets. The tablets are then coated with pigments, which are suspended in an aqueous solution consisting of coating and film-forming substances. In a tablet the active substance (I) is present in an amount of 5 mg. Examples 4-2 and 4-3 (dosage forms (tablets) containing amorphous solid dispersion (ASD)) The granulate obtained according to Example 3-1 is mixed with fillers, a disintegration promoter and a surfactant. active substance. This mixture is compacted with rollers and ground, followed by addition and mixing lubricants. The mixture thus obtained ready for pressing is pressed to obtain tablets. Then the tablets are coated with pigments that are suspended in an aqueous solution consisting of coating and film-forming agents substances. The active substance is present in tablets in amounts of 15 mg and 25 mg, respectively. Examples 4-4, 4-5 and 4-6 (dosage forms (tablets) containing amorphous solid dispersion (ASD)) The granules obtained according to Example 3-3 are mixed with a filler, a disintegration promoter and a surfactant. active substance. After that, add the lubricant and mix again. The resulting ready-to-use pressing the mixture is pressed to obtain tablets. In the tablets, the active substance (I) is present in an amount of 50 mg. Examples 4-7, 4-8, 4-9 and 4-10 (dosage forms (tablets) containing amorphous solid dispersion (ASD)) The granules obtained according to examples 3-4 or 3-5 are mixed together with the addition of a disintegration promoter and surfactant. This mixture can be compacted with rollers and ground. Then, a lubricant and mixed again. The mixture thus obtained ready for pressing is pressed to obtain tablets. The tablets can then be coated with pigments that are suspended in an aqueous solution consisting of coating and film-forming substances. In tablets, the active substance (I) is present in an amount of 20 mg or 50 mg. Examples 4-11 and 4-12 (dosage forms (tablets) containing amorphous solid dispersion (ASD)) The granules obtained in examples 3-5 can be compacted with rollers and ground. After that, they are mixed together with a lubricant. The mixture thus obtained ready for pressing is pressed to obtain tablets. The tablets can then be coated with pigments that are suspended in an aqueous solution consisting of coating and film-forming substances. In tablets, the active substance (I) is present in an amount of 20 mg or 50 mg. Examples 4-13, 4-14, 4-15, 4-16, 4-17 and 4-18 (dosage forms (tablets) containing amorphous solid dispersion (ASD)) The granules obtained according to examples 3-4, 3-5, 3-6, 3-7, 3-8 or 3-9 are mixed together with the addition of a promoter disintegration. This mixture can be compacted with rollers and crushed. Then the mixture is added with lubricant and again The mixture thus obtained is ready for pressing and is pressed to obtain tablets. Then tablets can be coated with pigments that are suspended in an aqueous solution consisting of coating and film-forming substances. In tablets, the active substance (I) is present in an amount of 20 mg or 50 mg. 5. Hot melt extrusion method Examples 5-1, 5-2, 5-4 and 5-5 (comminuted extrudates for comparison) Active ingredient (I), surfactant and solid dispersion base The mixture was extruded using a laboratory twin-screw extruder at at a temperature of 180 °C. The extruded material can be cut and subsequently crushed using an impact crusher. laboratory mill. The resulting granulate can be used as such or can be processed, for example, in sachets, capsules or tablets. Examples 5-3 and 5-6 (comminuted extrudates for comparison) The active ingredient (I) and the solid dispersion base are mixed / agglomerated. The mixture is extruded by using a laboratory twin-screw extruder at a temperature of 180 °C. The extruded material can be cut and subsequently ground using an impact laboratory mill. The resulting granulate can be applied in its pure form or can be processed, for example, into the form of sachets, capsules or tablets. 6. Composition of the dosage form in mg / dosage form 6.1 Liquid preparation and tablets as examples for comparison (Table 1) 1-1 1-2 2-1 2-2 2-3 Active substance (I), crystalline modification I 0.6 -- 5.0 -- -- Active substance (I), amorphous form -- 0.6 -- 50.0 5.0 Solid dispersion base (polymer) Polyvinylpyrrolidone (PVP) -- -- -- -- -- HPMCAS MG -- -- -- -- -- Kollidon VA64 -- -- -- -- -- Binder Hypromellose 3 cP -- -- 3.40 15.4 3.40 Solvent Water 954.4 499.7 68 440 68 Ethanol 99% -- 99.9 -- -- -- Acetone -- -- -- -- -- Fillers Microcrystalline cellulose -- -- 35.45 171.9 35.45 Lactose monohydrate -- -- 35.45 171.9 35.45 Tylose 5.0 -- -- -- -- Disintegration promoter Croscarmellose sodium -- -- 4.25 22.0 4.25 Surfactant Sodium lauryl sulfate -- -- 0.85 4.4 0.85 PEG 4000 -- -- -- -- -- PEG 6000 -- -- -- -- -- PEG 400 -- 399.8 -- -- -- Oil Magnesium stearate -- -- 0.60 4.4 0.60 Coating and film-forming agents and dyes / pigments Hypromellose 5cP -- -- 1.50 5.0 1.50 Hypromellose 15cP -- -- -- -- -- Polyethylene glycol 3350 -- -- 0.30 1.0 0.30 Red iron oxide -- -- 0.30 1.0 0.30 Talc -- -- 0.30 1.0 0.30 Titanium dioxide -- -- 0.60 2.0 0.60 Total amount [mg] 1000 1000 88 450 88 Format (mm) -- -- 6 16 × 7 6 Disintegration time (min) -- -- 3 6 5 Dissolution after 30 min [%] -- -- 43 [42-44] 88 [87-89] 95 [94-95] F rel [%] animals 11 100 -- -- -- AUC / D animal [kg*h / l] 0.491 4.43 -- -- -- Cmax / D animal [kg / l] 0.089 0.794 -- -- -- PXRD (initial) -- -- crystalline amorphous amorphous 6.2 Amorphous solid dispersion (ASD) (Table 2) 3-1 3-2 3-3 3-4 3-5 Active substance (I), crystalline modification I -- -- 5.0 -- -- Active substance (I), amorphous form 5.0 5.0 -- 5.0 5.0 Solid dispersion base (polymer) Polyvinylpyrrolidone (PVP) 10.0 10.0 10.0 10.0 10.0 HPMCAS MG -- -- -- -- -- Kollidon VA64 -- -- -- -- -- Binder Hypromellose 3 cP -- -- -- -- -- Solvent Water -- -- -- -- -- Ethanol 99% 60.0 30.0 6.0 6.0 15.0 Acetone -- -- 24.0 24.0 15.0 Fillers Microcrystalline cellulose 7.5 -- -- -- -- Lactose monohydrate -- -- -- -- -- Disintegration promoter Croscarmellose sodium 7.5 5.0 5.0 5.0 5.0 Surfactant Sodium lauryl sulfate -- -- -- -- -- PEG 4000 -- -- -- -- -- PEG 6000 -- -- -- -- -- PEG 400 -- -- -- -- -- Oil Magnesium stearate -- -- -- -- -- Total amount [mg] 30 20 20 20 20 Dissolution after 30 min [%] (initial) 102 [99-105] 97 [96-98] 94 [92-95] 92 [89-94] 101 [100- 102] Dissolution after 30 min [%]after 12 months at 25 °C / 60% relative humidity open storage -- -- -- -- 99 [96-100] F rel [%] animals 65 -- -- -- -- AUC / D animal [kg*h / l] 2.86 -- -- -- -- Cmax / D animal [kg / l] 0.610 -- -- -- -- PXRD (initial) amorphous amorphous amorphous amorphous amorphous PXRD after 1 month at 40 °C / 75% relative humidity open storage -- amorphous -- -- -- PXRD after 12 months at 25 °C / 60% relative humidity open storage -- -- -- -- amorphous PXRD after 18 months at 25 °C / 60% relative humidity closed storage amorphous -- -- -- -- PXRD after 24 months at 25°C / 60% amorphous -- -- -- -- relative humidity of the closed storage 3-6 3-7 3-8 3-9 Active substance (I), crystalline modification I -- -- -- -- Active substance (I), amorphous form 5.0 5.0 5.0 5.0 Solid dispersion base (polymer) Polyvinylpyrrolidone (PVP) -- -- -- 15.0 HPMCAS MG -- 10.0 -- -- Kollidon VA64 10.0 -- 15.0 -- Binder Hypromellose 3 cP -- -- -- -- Solvent Water -- -- -- -- Ethanol 99% 15.0 -- 15.0 15.0 Acetone 15.0 70.0 15.0 15.0 Fillers Microcrystalline cellulose -- -- -- -- Lactose monohydrate -- -- -- -- Disintegration promoter Croscarmellose sodium 5.0 5.0 5.0 5.0 Surfactant Sodium lauryl sulfate -- -- -- -- PEG 4000 -- -- -- -- PEG 6000 -- -- -- -- PEG 400 -- -- -- -- Oil Magnesium stearate -- -- -- -- Total amount [mg] 20 20 25 25 Dissolution after 30 min [%] (initial) 100 [99-101] 11 [9-14] 100 [98-100] 100 [98-101] Dissolution after 30 min [%] after 1 month at 40 °C / 75 % relative humidity humidity of open storage 78 [70-84] 25 [24-25] 52 [49-56] 88 [87-89] F rel [%] animals -- -- -- -- AUC / D animal [kg*h / l] -- -- -- -- Cmax / D animal [kg / l] -- -- -- -- PXRD (initial) amorphous amorphous amorphous amorphous PXRD after 1 month at 40 °C / 75% relative humidity open storage amorphous amorphous amorphous amorphous PXRD after 18 months at 25 °C / 60% relative humidity closed storage -- -- -- -- 6.3 Solid dosage forms (tablets) containing amorphous solid dispersion (ASD); method of preparation - fluidized bed granulation (Table 3) 4-1 4-2 4-3 4-4 4-5 4-6 4-7 Active ingredient (I), crystalline modification I -- -- -- 50.0 50.0 50.0 -- Active ingredient (I), amorphous form 5.0 15.0 25.0 -- -- -- 50.0 Solid dispersion base (polymer) Polyvinylpyrrolidone (PVP) 10.0 30.0 50.0 100.0 100.0 100.0 100.0 HPMCAS MG -- -- -- -- -- -- -- Kollidon VA64 -- -- -- -- -- -- -- Binder Hypromellose 3 cP -- -- -- -- -- -- -- Solvent Water -- -- -- -- -- -- -- Ethanol 99% 60.0 180.0 300.0 60.0 60.0 60.0 300.0 Acetone -- -- -- 240.0 240.0 240.0 -- Fillers Microcrystalline cellulose 7.5+155 22.5+100 37.5+50.0 110.0 84.7 64.7 -- Lactose monohydrate 60.0 40.0 20.0 -- -- -- -- Disintegration promoter Croscarmellose sodium 7.5 22.5+15.0 37.5+25.0 50.00+40.00 50.00+40.00 50.00+40.00 50.00+46.25 Surfactant Lauryl sulfate sodium 2.5 2.5 2.5 3.5 3.5 3.5 2.5 PEG 4000 -- -- -- -- -- -- -- PEG 6000 -- -- -- -- -- -- -- PEG 400 -- -- -- -- -- -- -- Oil Magnesium stearate 2.5 2.5 2.5 1.8 1.8 1.8 1.25 Coating and film-forming agents and dyes / pigments Hypromellose 5cP -- -- -- -- -- -- -- Hypromellose 15cP 4.2 4.2 4.2 -- -- -- -- Polyethylene glycol 3350 1.4 1.4 1.4 -- -- -- -- Red oxide iron 0.042 0.042 0.042 -- -- -- -- Yellow oxide iron -- -- -- -- -- -- -- -- Talc -- -- -- -- -- -- -- Titanium dioxide 1.358 1.358 1.358 -- -- -- -- Total number [mg] 257 257 257 355.3 330 310 250 Format (mm) 12 × 6 12 × 6 12 × 6 14 × 7 14 × 7 14 × 7 12 × 6 Disintegration time (min) 5 4 8 10 9 10 14 Dissolution 98 [97- 98 [95- 99 [96- 90 93 [91- 93 [92- 103 [102- after 30 min [%] (initial) 100] 100] 101] [89-91] 95] 95] 104] Dissolution through 30 min [%] after 30 months at 25°C / 60% relative humidity closed storage 101 [97-107] 100 [94-104] 105 [102- 107] -- -- -- -- PXRD (initial) amorphous amorphous amorphous -- amorphous amorphous amorphous PXRD after 18 months at 25°C / 60% relative humidity closed storage amorphous amorphous amorphous -- -- -- -- PXRD after 30 months at 25°C / 60% relative humidity closed storage amorphous amorphous amorphous -- -- -- -- 4-8 4-9 4-10 4-11 4-12 4-13 Active substance (I), crystalline modification I -- -- -- -- -- -- The active substance (I) is amorphous form 20.0 50.0 20.0 20.0 50.0 20.0 Solid dispersion base (polymer) Polyvinylpyrrolidone (PVP) 40.0 100.0 40.0 40.0 100.0 40.0 HPMCAS MG -- -- -- -- -- -- Kollidon VA64 -- -- -- -- -- -- Binder Hypromellose 3 cP -- -- -- -- -- -- Solvent Water -- -- -- -- -- -- Ethanol 99% 96.0 150.0 60.0 60.0 150.0 60.0 Acetone 24.0 150.0 60.0 60.0 150.0 60.0 Fillers Microcrystalline cellulose -- -- -- -- -- -- Lactose monohydrate -- -- -- -- -- -- Disintegration promoter Croscarmellose sodium 20.0+18.50 50.0+46.25 20.0+18.50 20.0 50.0 20.0+ 6.0 Surfactant Sodium lauryl sulfate 1.0 2.5 1.0 -- -- -- PEG 4000 -- -- -- -- -- -- PEG 6000 -- -- -- -- -- -- PEG 400 -- -- -- -- -- -- Oil Magnesium stearate 0.50 1.25 0.50 0.40 1.00 0.40 Coating and film-forming agents and dyes / pigments Hypromellose 5cP -- -- -- -- -- -- Hypromellose 15cP -- 3.00 1.80 1.80 3.00 1.56 Polyethylene glycol 3350 -- 1.00 0.60 0.60 1.00 0.52 Red iron oxide -- 0.03 0.018 0.018 0.03 0.0156 Yellow iron oxide -- -- -- -- -- -- Talc -- -- -- -- -- -- Titanium dioxide -- 0.97 0.582 0.582 0.97 0.5044 Total amount [mg] 100 255 103 83 206 89 Format (mm) 7 12 × 6 7 6 12 × 6 6 Disintegration time (min) 7 14 7 11 13 9 Dissolution after 30 min [%] (initial) 100 [100-101] 100 [98-101] 100 [100-101] 102 [101-103] 100 [99-102] 98 [96-100] Dissolution after 30 min [%]; after 9 months at 30 °C / 75 % relative humidity of the closed storage -- -- -- -- -- 95 [94-98] PXRD (initial) amorphous -- -- -- -- amorphous PXRD, after 1 month at 40 °C / 75% relative humidity open storage -- amorphous amorphous amorphous -- -- PXRD, after 9 months at 30 °C / 75% relative humidity closed storage -- -- -- -- -- amorphous 4-14 4-15 4-16 4-17 4-18 Active substance (I), crystalline modification I -- -- -- -- -- Active ingredient (I) amorphous form 50.0 50.0 50.0 50.0 50.0 Solid dispersion base (polymer) Polyvinylpyrrolidone (PVP) 100.0 -- -- -- 150.0 HPMCAS MG -- -- 100.0 -- -- Kollidon VA64 -- 100.0 -- 150.0 -- Binder Hypromellose 3 cP -- -- -- -- -- Solvent Water -- -- -- -- -- Ethanol 99% 150.0 150.0 -- 150.0 150.0 Acetone 150.0 150.0 700.0 150.0 1500 Fillers Microcrystalline cellulose -- -- -- -- -- Lactose monohydrate -- -- -- -- -- Disintegration promoter Croscarmellose sodium 50.0+ 15.0 5.0+15.0 5.0+15.0 5.0+15.0 5.0+15.0 Surfactant Sodium lauryl sulfate -- -- -- -- -- PEG 4000 -- -- -- -- -- PEG 6000 -- -- -- -- -- PEG 400 -- -- -- -- -- Oil Magnesium stearate 1.00 1.0 1.0 1.0 1.0 Coating and film-forming agents and dyes / pigments Hypromellose 5cP -- -- -- -- -- Hypromellose 15cP 2.4 -- -- -- -- Polyethylene glycol 3350 0.8 -- -- -- -- Red iron oxide 0.024 -- -- -- -- Yellow iron oxide -- -- -- -- -- Talc -- -- -- -- -- Titanium dioxide 0.776 -- -- -- -- Total amount [mg] 220 216 216 266 266 Format (mm) 12 × 6 12 × 6 12 × 6 12 × 6 12 × 6 Disintegration time (min) 13 39 10 > 40 19 Dissolution after 30 min [%] (initial) 99 [98-100] 10 [9-12] 64 [58-69] 12 [12-14] 91 [88-94] Dissolution after 30 min [%] after 1 month at 40 °C / 75 % relative humidity humidity of the open storage -- 53 [52-55 93 [90-98] 17 [17-18] 95 [91-96] Dissolution after 30 min [%] after 6 months at 40 °C / 75 % relative humidity of the open storage 96 [91-100] -- -- -- -- Dissolution after 30 min [%] after 9 months with 30 °C / 75 % relative humidity 100 [98-102] -- -- -- -- indoor humidity storage PXRD (initial) amorphous amorphous amorphous amorphous amorphous PXRD, after 1 month at 40 °C / 75 % relative humidity of the open storage -- -- -- -- -- PXRD, after 6 months at 40 °C / 75 % relative humidity of the open storage amorphous -- -- -- -- PXRD, after 9 months amorphous -- -- -- -- at 30 °C / 75 % relative humidity indoor humidity storage 6.4 Solid dosage forms (milled extrudates) containing amorphous solid dispersion (ASD); method hot melt extrusion (comparative examples) (Table 4) 5-1 5-2 5-3 5-4 5-5 5-6 Active substance (I), crystalline modification I -- -- -- 50.0 50.0 50.0 Active ingredient (I) amorphous form 50.0 50.0 50.0 -- -- -- Solid dispersion base (polymer) Polyvinylpyrrolidone (PVP) 100.0 100.0 -- 100.0 100.0 -- HPMCAS MG -- -- -- -- -- -- Kollidon VA64 -- -- 100.0 -- -- 100.0 Binder Hypromellose 3 cP -- -- -- -- -- -- Solvent Water -- -- -- -- -- -- Ethanol 99% -- -- -- -- -- -- Acetone -- -- -- -- -- -- Fillers Microcrystalline cellulose -- -- -- -- -- -- Lactose monohydrate -- -- -- -- -- -- Disintegration promoter Croscarmellose sodium -- -- -- -- -- -- Surfactant Sodium lauryl sulfate -- -- -- -- -- -- PEG 4000 11.1 -- -- 11.1 -- -- PEG 6000 -- 11.1 -- -- 11.1 -- PEG 400 -- -- -- -- -- -- Oil Magnesium stearate -- -- -- -- -- -- Total amount [mg] 161.1 161.1 150 161.1 161.1 150 PXRD (initial) amorphous amorphous amorphous amorphous amorphous amorphous 7. Bioavailability, dissolution and results 7.1 Comparison of liquid formulations and amorphous solid dispersions (ASD) (in animal models) The liquid preparations of Comparative Examples 1-1 and 1-2 and the amorphous solid dispersion of Example 3-1 were tested in rats. Single doses were administered to male rats (4 rats). The liquid preparation was a suspension of the active substance (I) in crystalline modification I in aqueous 0.5% tylose solution (example 1-1). The amorphous solid dispersion granulate of Example 3-1 was suspended in water before administration. Examples 1-1 and 3-1 were tested against the PEG solution of example 1-2. Animals (male rats) were administered 3.00 mg of active substance (I) / kg body weight. The volume of solution for The dose was 5.00 ml / kg body weight. Approximately 0.5 ml of whole blood was collected via a jugular catheter. at 0, 0.25, 0.5, 0.75, 1, 2, 3, 5, 7, 24, 30 and 48 hours after administration. Blood samples were centrifuged for obtaining plasma, which was then transferred into appropriately labeled vials and stored frozen (< 15 °C) prior to analysis. Plasma samples were analyzed by HPLC / MSC to determine the concentration of the active substance (I) and calculated pharmacokinetic parameters. The results are presented in Table 5. Table 5 Comparison of exposure of active substance (I) in rats for examples 1-1, 1-2 and 3 1 1-1 Example comparison 1-2 Example comparison 3-1 Amorphous solid dispersion (ASD) Dose [mg / kg] 3.00 3.00 3.00 AUC [kg*h / l] 0.491 4.43 2.86 Cmax [kg / l] 0.089 0.794 0.610 Frel [%] 11 100 65 Result: AUC and cmax data indicate significant differences in exposure of the active substance (I) after oral administration of liquid preparations of examples 1-1 and 1-2 and amorphous solid dispersion (ASD) of example 3-1. The PEG solution from Example 1-2 is used as a 100% reference standard. The exposure obtained after administration of the amorphous solid dispersion (ASD) of example 3-1, significantly higher compared to exposure to liquid preparations example 1-1. AUC increases by approximately 5.8 times and cmax increases by approximately 6.8 times for amorphous solid dispersion (ASD) of example 3-1. Active substance (I) exhibits low bioavailability and a worse dissolution profile when the active substance is (I) is used in crystalline modification I. The active substance (I) in crystalline modification I demonstrates relative bioavailability of only 11% (example 1-1), while an amorphous solid dispersion containing the active substance (I) in amorphous form, demonstrates a relative bioavailability of 65% (Example 3-1) when administered to rats. This proves that absorption and oral exposure are significantly improved when the active substance is administered (I) in amorphous form dissolved in liquid (example 1-2) or in the form of an amorphous solid dispersion (ASD) of example 3-1, containing the active substance (I) in the form of an amorphous solid dispersion, compared to the liquid form of the example 1-1, which mimics the standard IR tablet of example 2-1, containing the active substance (I) in crystalline modification I. Amorphous solid dispersion (ASD) provides a stabilized amorphous active ingredient (I) that does not exhibit the risk of crystallization compared to a standard infrared tablet (example 2-1, comparison example). 7.2 Comparison of standard IR tablets with PEG solution (in humans) Comparative Examples 2-1, 2-2 and 2-3 were obtained by fluidized bed granulation. In Comparative Examples 2-2 and 2-3, the active ingredient (I) in amorphous form is used to obtain tablets with a dosage of 50 mg (example 2-2) and 5 mg (example 2-3). A tablet containing 5 mg of active substance (I), was tested at a dose of 25 mg (5 tablets of 5 mg of active substance (I)) against the PEG solution from example 1-2 on The results are presented in Table 6. Table 6 Comparison of exposure of active substance (I) in humans for examples 1-2 and 2-3 Treatment AUC / D (hr / L) Cmax / D (1 / L) IR tablets 5 × 5 mg from example 2-3 0.237 0.0128 25 mg of PEG solution from example 1-2 0.265 0.0149 Ratio / rel. BA 89.5% 86.0% Result: Comparative Example 2-3 showed a relative BA of 89.5% for AUC / D and 86.0% for Cmax / D compared to PEG solution from example 1-2. If the same excipients and excipient concentrations are used, but the active substance (I) is used in the form of crystalline modification I (comparative example 2 - compared to amorphous form in Comparative Examples 2-2 and 2-3, the dissolution rate decreases sharply. The results are presented in table 7. Table 7 Comparison of dissolution profiles for examples 2-1 and 2-2 and 2-3 Time points [min] 5 10 15 30 45 60 example 2-3 [%] -- -- 98.2 98.6 98.8 98.7 example 2-2 [%] -- -- 101.5 100.2 99.5 98.8 example 2-1 [%] 20.4 32.5 37.8 43.0 47.1 49.7 Result: The dissolution results of Comparative Example 2-1 are clearly inferior compared to the comparative examples 2-2 and 2-3, indicating reduced bioavailability (see figure 1). Comparative Examples 2-2 and 2-3 contain the active ingredient (I) in amorphous form without any stabilizers. (e.g. polymers), which creates a risk of crystallization. If crystallization occurs, bioavailability will be reduced. 7.3 Comparison of amorphous solid dispersions (ASD) with liquid preparations (in an animal model) The amorphous solid dispersion (ASD) of Examples 3-1 to 3-5 is prepared by granulation in fluidized bed. The polymer used serves as a stabilizer to prevent crystallization. Active substance (I) in crystalline modification I, used in example 3-3, is converted into an amorphous state by using this production process. A mixture of filler and promoter can be used as a carrier disintegration (example 3-1) or only the disintegration promoter (examples 3-2-3-5). The solvent can be either ethanol (example 3-1 and example 3-2), and mixtures of ethanol and acetone (examples 3-3-3-5). Exposure of active substance (I) from amorphous solid dispersion (ASD) (Example 3-1) compared to liquid preparations (examples 1-1 and 1-2) is shown in Table 5. 7.4 Comparison of amorphous solid dispersion (ASD) dosage forms with standard IR tablets (in person) Examples 4-1 to 4-14 describe dosage forms (tablets) containing an amorphous solid dispersion (ASD) of using the granules obtained in examples 3-1 to 3-5. In examples 4-1-4-3, the granulate of example 3-1 is formed in tablets with different amounts of active ingredient (I) and different amounts of additional excipients. Table 8 Comparison of dissolution profiles of examples 4-1 with 4-3 and 4-14 with comparative example 2-2 Time points [min] 0 15 30 45 60 example 4-1 [%] -- 89.6 98.5 99.4 99.1 example 4-2 [%] -- 96.0 98.2 96.7 96.7 example 4-3 [%] -- 91.0 99.3 99.0 98.4 example 4-14 [%] -- 73 99 99 99 example 2-2 [%] -- 101.5 100.2 99.5 98.8 Result: For all examples (examples 4-1 to 4-3 and 4-14) the dissolution profiles can be compared with the profile dissolution of comparative example 2-2. Example 4-3 describes dosage forms (tablets) containing an amorphous solid dispersion (ASD) of using the granules obtained in Example 3-1. A tablet containing 25 mg of active ingredient (I), was tested in humans at a dose of 25 mg compared to the 50 mg tablet of Example 2-2. Results are presented in Table 9. Table 9 Comparison of exposure of active substance (I) in humans for examples 4-3 and 2-2 Treatment AUC / D (hr / L) Cmax / D (1 / L) Tablet 25 mg ASD from example 4-3 0.253 0.0134 50 mg IR tablets from example 2-2 0.268 0.0141 Ratio / rel. BA 94.3% 95.5% Examples 4-14 describe pharmaceutical dosage forms (tablets) containing an amorphous solid dispersion (ASD) using the granules obtained in examples 3-5. A tablet containing 50 mg of active ingredient (I), was tested in humans at a dose of 50 mg compared to the 25 mg dose from Example 4.3. The results are presented in Table 9a. Table 9a Comparison of exposure of active substance (I) in humans for examples 4-3 and 4 14 Treatment AUC / D (hr / L) Cmax / D (1 / L) ASD 25 mg tablet from example 4-3 0.268 0.0141 ASD 50 mg tablet from example 4-14 0.254 0.0126 Ratio / rel. BA 94.9% 88.8% Result: Tablets (Example 4-3) obtained using the amorphous solid dispersion (ASD) from Example 3-1, showed high relative bioavailability in humans (relative bioavailability 94.3% for AUC / D and 95.5% for Cmax / D) compared to the IR tablet of example 2-2. In addition, tablets (examples 4-14) obtained using amorphous solid dispersion (ASD) from example 3-5, showed high relative bioavailability in humans (relative bioavailability 94.9% for AUC / D and 88.8% for Cmax / D) compared to the tablets of Example 4-3. It can be done conclusion that the technology of obtaining granulate in a fluidized bed leads to high bioavailability, since it converts the active substance (I) into an amorphous form regardless of the initial modification of the active substance (I) (amorphous form or crystalline modification of I) used in the process, and at the same time stabilizes the active substance (I) in an amorphous form to prevent crystallization. That thanks to the use of fluidized bed granulation and excipients according to this invention the main effect of the modification of the active substance (I) (amorphous form or crystalline modification of I) is eliminated on bioavailability in humans, since the original polymorphic form used to obtain ASD during technological method of production will be converted into a polymer-stabilized amorphous form, proven Examples 4-4 to 4-6. In these Examples 4-4 to 4-6, the amorphous solid dispersion (ASD) of Example 3-3 is used to obtain tablets containing different amounts of filler in the tablet. It can be made conclusion that the amount of filler is not critical for the rapid dissolution of the active substance (I), and all Examples 4-4 to 4-6 allow tablets with the required dissolution characteristics to be obtained. Even reducing the amount of filler to zero in example 4-7 (using amorphous solid dispersion (ASD) example 3-2) was possible to obtain tablets with a dose of 50 mg with the required characteristics dissolution. In Example 4-8, the amorphous solid dispersion (ASD) of Example 3-4 was used to demonstrate that elimination of the filler in the post-blend is also possible to obtain a 20 mg tablet with the necessary dissolution characteristics. In examples 4-9 to 4-14, the granulate of example 3-5 was used to obtain tablets with different content / amount of disintegration promoter. It has been shown that a wide range of range down to zero content of disintegration promoter at the post-mixing stage, achieving the most necessary dissolution properties of the active ingredient (I) in the tablet. In examples 4-11 to 4-14 it was shown that that it is also possible to achieve the required dissolution properties of the active ingredient (I) in the tablet without the use of sodium lauryl sulfate as a surfactant. Comparison of tablet dissolution rates of the active substance (I) in examples 4-1 to 4-14 are given in Table 3. Comparison of different polymers as a solid dispersion base: In examples 4-15 and 4-17, Kollidon VA64 was used as the solid dispersion base, and in example 4-16- HPMCAS MG. Surprisingly, the obtained dissolution values ​​remain very low (e.g. 4-15: 11%, e.g. 4-16: 65%, e.g. 4-17: 13%) and do not meet the active substance release criterion (I) at least 85% after 30 minutes. In addition, especially with Kollidon VA 64 tablets, a long-term decay time exceeding 35 minutes. It can be concluded that neither HPMCAS MG nor Kollidon VA64 are suitable to achieve the required dissolution criterion - release of the active substance (I) by at least 85% through 30 minutes. This clearly shows the advantage of PVP chosen as the base for the solid solution. In example 4-18, the granulate of examples 3-9 was used to obtain tablets containing the ratio of active ingredient (I) to solid dispersion base 1:3. Example 4-18 meets the dissolution criteria, which consists in releasing the active substance (I) by at least 85% after 30 minutes, but reveals almost 1.5 times longer disintegration time and reduced drug load compared to example 4-14. 7.5 Hot melt extrusion for the production of dosage forms containing the active substance (I) - Impact on enantiomeric purity The hot melt extrusion method generated a large amount of the wrong enantiomer, which is known to be inactive for humans, regardless of the solid dispersion base or surfactant used or modifications of the active substance (I) (amorphous form or crystalline modification I). Research results are presented in Table 10. Table 10 The effect of melt extrusion and fluidized bed granulation on the enantiomeric purity of the active substances (I) Granulate according to example Number of incorrect enantiomers at the beginning of the active substance (I) Number of incorrect enantiomer in granulate 5-1 < 0.2% 4.5% 5-2 < 0.2% 3.6% 5-3 < 0.2% 5.8% 5-4 1.2% 8.8% 5-5 1.2% 8.5% 5-6 1.2% 5.9% 3-1 < 0.2% < 0.2% 3-4 < 0.2% < 0.2% 3-5 < 0.2% < 0.2% Result: For the hot melt extrusion method (Examples 5-1 to 5-6 of Table 10) the formation of the incorrect enantiomer, which is ineffective in-vivo, is clearly increased compared to the initial enantiomeric purity of the active substance (I). Therefore, hot melt extrusion is not considered appropriate Unlike the hot melt extrusion method, the fluidized bed granulation method does not leads to an increase in the formation of the wrong enantiomer of the active substance (I) (examples 3-1, 3-4 and 3-5 from table 10). This indicates that the active substance (I) must be present in amorphous form, which is necessary prevent crystallization of the active substance (I) and ensure enantiomeric purity during preparation and storage of tablets (dosage form) containing the active substance (I). These data confirm that the amorphous solid dispersion (ASD) containing the amorphous active ingredient (I) stabilized with polyvinylpyrrolidone (PVP) and croscarmellose sodium and manufactured by granulation in fluidized bed, exhibits excellent dissolution behavior, characterized by the release of active of substance (I) by at least 85% after 30 minutes. In addition, the enantiomeric purity is maintained, the amorphous the solid dispersion containing the active ingredient (I) demonstrates (long-term) stability when open stored at 40 °C and 75% relative humidity (harsh conditions), and bioavailability is good even for tablets (dosage form) stored under these harsh conditions. The results are shown in Table 3. 8. Disintegration method According to the European Pharmacopoeia, 10th edition, latest revision of the monograph 01 / 2020, solid medicinal products Oral dosage forms are tested in a rigid rack-and-pin apparatus. Six The test samples are placed individually in the basket tube and a disk is added. The apparatus operates with using water as a medium at a temperature of 37 + / - 2 °C. The results are shown in Table 1 and Table 3. 9. PXRD method Powder X-ray diffraction (PXRD) data were recorded on a STOE STADI P diffractometer with using monochromatized Cu-K alpha-1 radiation, sensitive to the detector position, with generator settings of 40 kV and 40 mA. Samples were collected in the transient mode and prepared as a thin layer between two foils. The scanning angle was from 10° to 26° 2 theta in 0.1° increments at 60 seconds / stage. 10. Solubility The solubility of the active substance (I) in crystalline form was determined in various solvents. Results are presented in Table 11. Table 11 Solubility of the active substance (I) in crystalline form in various solvents Ethanol content [%] Acetone content [%] Solubility* [µg / ml] 100 0 35000 50 50 180000 0 100 80000 * solubility may vary slightly between batches 11. Explanation of figures Figure 1: Comparison of dissolution profile for examples 2-1, 2-2 and 2-3, demonstrating the effect of application of the active substance (I) in crystalline modification I.

Claims

1. Solid dosage form for oral administration, which contains an amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14- (trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphan- 74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix, where the drug the loading of the active substance (I) in the amorphous solid dispersion (ASD) is >20%, and wherein the pharmaceutically acceptable matrix consists of a combination of a solid dispersion base and carrier, where the ratio of active substance (I) and solid dispersion base is from 1:2 to 1:3, and where the solid dispersion base is the polymer polyvinylpyrrolidone (PVP), and the carrier is a disintegration promoter, and the disintegration promoter is croscarmellose sodium.

2. Solid dosage form for oral administration according to claim 1, comprising a) amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix, where the drug load of the active substance (I) in an amorphous solid dispersion (ASD) is >20%, and wherein the pharmaceutically acceptable matrix consists of a combination of solid dispersion base and carrier, where the ratio of active substance (I) and solid dispersion base is from 1:2 to 1:3, and where the solid dispersion base is a polymer polyvinylpyrrolidone (PVP), b) at least one lubricant, c) at least one disintegration promoter, wherein the disintegration promoter is croscarmellose sodium.

3. The solid dosage form for oral administration according to claim 2, further comprising d) one or more fillers.

4. The solid dosage form for oral administration according to claim 2, further comprising e) one or more surfactants.

5. A solid dosage form for oral administration according to any one of claims 1-4, which differs in that the dosage form is a tablet.

6. Amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole-2(1,2),7(1)- dibenzeneheptaphane-74-carboxamide (active ingredient (I)) in a pharmaceutically acceptable matrix, where the drug load of the active substance (I) in an amorphous solid dispersion (ASD) is >20%, and wherein the pharmaceutically acceptable matrix consists of a combination of solid dispersion base and carrier, where the ratio of active substance (I) and solid dispersion base is from 1:2 to 1:3, and where the solid dispersion base is a polymer polyvinylpyrrolidone (PVP), and the carrier is a disintegration promoter, and the disintegration promoter is croscarmellose sodium.

7. The amorphous solid dispersion (ASD) according to claim 6, further comprising sweeteners, flavorings and colorings.

8. The amorphous solid dispersion (ASD) according to claim 6 or 7, characterized in that (4S)-24-chloro-4- ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)- [1,2,3]triazole-2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active ingredient (I)) is present in amorphous form.

9. The amorphous solid dispersion (ASD) according to claim 6, wherein the carrier is selected from the groups fillers, lubricants, disintegration promoters, surfactants, sweeteners, flavors and / or colors or combinations thereof.

10. Method for obtaining an amorphous solid dispersion (ASD) containing (4S)-24-chloro-4-ethyl-73- fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32H-6-aza-3(4,1)-pyridine-1(1)-[1,2,3]triazole- 2(1,2),7(1)-dibenzeneheptaphane-74-carboxamide (active substance (I)), according to claim 6, which differs in that the amorphous solid dispersion (ASD) is obtained by wet granulation, which uses a mixture of ethanol and acetone.

11. The method according to claim 10, characterized in that the amorphous solid dispersion (ASD) is obtained by granulation in a fluidized bed, in which the active substance (I) is dissolved in granulating liquid, which contains a mixture of 50% ethanol and 50% acetone, and is introduced into the granulator fluidized bed.

Citation Information

Patent Citations

  • Substituted oxopyridine derivatives

    WO2017005725A1

  • Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations

    WO2020210629A1